Company’s 36-month beta value is 0.72.Analysts have differing opinions on the stock, with 8 analysts rating it as a “buy,” 7 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMVT is 61.90M, and currently, short sellers hold a 19.76% ratio of that floaft. The average trading volume of IMVT on September 06, 2024 was 984.42K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IMVT) stock’s latest price update
Immunovant Inc (NASDAQ: IMVT)’s stock price has increased by 9.55 compared to its previous closing price of 30.69. However, the company has seen a 7.24% increase in its stock price over the last five trading sessions. zacks.com reported 2024-09-05 that Immunovant (IMVT) reported earnings 30 days ago. What’s next for the stock?
IMVT’s Market Performance
Immunovant Inc (IMVT) has seen a 7.24% rise in stock performance for the week, with a 20.72% gain in the past month and a 31.33% surge in the past quarter. The volatility ratio for the week is 4.57%, and the volatility levels for the past 30 days are at 4.25% for IMVT. The simple moving average for the last 20 days is 9.89% for IMVT stock, with a simple moving average of 2.77% for the last 200 days.
Analysts’ Opinion of IMVT
Many brokerage firms have already submitted their reports for IMVT stocks, with Oppenheimer repeating the rating for IMVT by listing it as a “Outperform.” The predicted price for IMVT in the upcoming period, according to Oppenheimer is $50 based on the research report published on March 28, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see IMVT reach a price target of $50. The rating they have provided for IMVT stocks is “Buy” according to the report published on March 13th, 2024.
JP Morgan gave a rating of “Overweight” to IMVT, setting the target price at $51 in the report published on February 20th of the current year.
IMVT Trading at 15.12% from the 50-Day Moving Average
After a stumble in the market that brought IMVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.24% of loss for the given period.
Volatility was left at 4.25%, however, over the last 30 days, the volatility rate increased by 4.57%, as shares surge +24.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.20% upper at present.
During the last 5 trading sessions, IMVT rose by +7.24%, which changed the moving average for the period of 200-days by -0.30% in comparison to the 20-day moving average, which settled at $30.93. In addition, Immunovant Inc saw -20.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMVT starting from Levine Mark S., who sale 3,295 shares at the price of $31.86 back on Aug 21 ’24. After this action, Levine Mark S. now owns 330,099 shares of Immunovant Inc, valued at $104,976 using the latest closing price.
Macias William L., the Chief Medical Officer of Immunovant Inc, sale 3,027 shares at $31.86 during a trade that took place back on Aug 21 ’24, which means that Macias William L. is holding 368,332 shares at $96,437 based on the most recent closing price.
Stock Fundamentals for IMVT
Current profitability levels for the company are sitting at:
- -189.93 for the present operating margin
- 0.63 for the gross margin
The net margin for Immunovant Inc stands at -181.7. The total capital return value is set at -0.52. Equity return is now at value -64.54, with -57.93 for asset returns.
Based on Immunovant Inc (IMVT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -3522.55.
Currently, EBITDA for the company is -269.98 million with net debt to EBITDA at 1.94. When we switch over and look at the enterprise to sales, we see a ratio of 2907.28. The receivables turnover for the company is 0.62for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.08.
Conclusion
In a nutshell, Immunovant Inc (IMVT) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
